NO20012444L - Krystaller av 5-[{6-(2-fluorbenzyl)oksy-2-naftyl}metyl]2,4- tiazolidindion, fremgangsmåte for deres fremstilling ogfarmasöytisk preparat omfattende slike - Google Patents
Krystaller av 5-[{6-(2-fluorbenzyl)oksy-2-naftyl}metyl]2,4- tiazolidindion, fremgangsmåte for deres fremstilling ogfarmasöytisk preparat omfattende slikeInfo
- Publication number
- NO20012444L NO20012444L NO20012444A NO20012444A NO20012444L NO 20012444 L NO20012444 L NO 20012444L NO 20012444 A NO20012444 A NO 20012444A NO 20012444 A NO20012444 A NO 20012444A NO 20012444 L NO20012444 L NO 20012444L
- Authority
- NO
- Norway
- Prior art keywords
- crystals
- preparation
- thiazolidinedione
- fluorobenzyl
- oxy
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 5
- 238000002360 preparation method Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 title 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 abstract 1
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000010586 diagram Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Photoreceptors In Electrophotography (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Cosmetics (AREA)
Abstract
Oppfinnelsen angår krystalltype A av 5-[{6-(2- fluorbenzyl)oksy-2-nafryl} metyl] 2,4-tiazolidindion som er kjennetegnet ved at den har karakteristiske absorpsjonstopper (26) ved 11,5° ± 0,3°, 14,5° ± 0,2°, 16,2° ± 0,3°, 17,0° ± 0,3°, 17,7° ± 0,2°, 18,6° ± 0,3°, 19,1° ± 0,2°, 21,3° ± 0,4°, 22,4° ± 0,5°, 25,7° ± 0,5° og 28,3° ± 0,5° i et diagram tatt opp med pulverrønt- gendiffraksj onsmønster. Det beskrives også en fremgangsmåte for fremstilling av krystallene, og et farmasøytisk preparat omfattende samme. Krystallene har utmerket stabilitet og har fordeler ved håndtering, lagring og fremstilling av farmasøytiske preparater. Oppfinnelsen angår også krytsalltyper B, C og D av den nevnte forbindelse.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP33054698 | 1998-11-20 | ||
| PCT/JP1999/006492 WO2000031055A1 (en) | 1998-11-20 | 1999-11-19 | Chrystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20012444D0 NO20012444D0 (no) | 2001-05-18 |
| NO20012444L true NO20012444L (no) | 2001-07-18 |
Family
ID=18233859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20012444A NO20012444L (no) | 1998-11-20 | 2001-05-18 | Krystaller av 5-[{6-(2-fluorbenzyl)oksy-2-naftyl}metyl]2,4- tiazolidindion, fremgangsmåte for deres fremstilling ogfarmasöytisk preparat omfattende slike |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US6541493B1 (no) |
| EP (1) | EP1131310B1 (no) |
| JP (1) | JP3784001B2 (no) |
| KR (1) | KR100652326B1 (no) |
| CN (1) | CN1326449A (no) |
| AT (1) | ATE315552T1 (no) |
| AU (1) | AU1185100A (no) |
| BR (1) | BR9916795A (no) |
| CA (1) | CA2351727C (no) |
| CZ (1) | CZ20011763A3 (no) |
| DE (1) | DE69929476T2 (no) |
| ES (1) | ES2257104T3 (no) |
| HU (1) | HUP0104139A3 (no) |
| ID (1) | ID30064A (no) |
| IL (1) | IL143177A0 (no) |
| NO (1) | NO20012444L (no) |
| NZ (1) | NZ512429A (no) |
| PL (1) | PL348502A1 (no) |
| PT (1) | PT1131310E (no) |
| TR (4) | TR200101901T2 (no) |
| TW (2) | TWI250156B (no) |
| WO (1) | WO2000031055A1 (no) |
| ZA (1) | ZA200104081B (no) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1131310E (pt) * | 1998-11-20 | 2006-05-31 | Mitsubishi Chem Corp | Cristais de 5-[{6-(2-fluorobenzil)oxi-2-naftil}metil]-2,4-tiazolidinadiona |
| JP2003514807A (ja) * | 1999-11-19 | 2003-04-22 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 固態形の５−［［６−［（２−フルオロフェニル）メトキシ］−２−ナフタレニル］メチル］−２，４−チアゾリジンジオン |
| JP4590159B2 (ja) * | 2001-04-04 | 2010-12-01 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法 |
| WO2007049050A2 (en) * | 2005-10-27 | 2007-05-03 | Heptahelix Ab | Modulators of gpr40 for the treatment of diabetes |
| NZ587094A (en) | 2008-02-04 | 2011-07-29 | Pfizer Ltd | Polymorphic form of a [1, 2, 4] triazolo [4, 3-a] pyridine derivative for treating inflammatory diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5594016A (en) * | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
| JP2845743B2 (ja) | 1992-12-28 | 1999-01-13 | 三菱化学株式会社 | 新規なナフタレン誘導体 |
| JP4023697B2 (ja) | 1996-11-14 | 2007-12-19 | 三菱化学株式会社 | ナフタレン誘導体の製造方法 |
| PT1131310E (pt) * | 1998-11-20 | 2006-05-31 | Mitsubishi Chem Corp | Cristais de 5-[{6-(2-fluorobenzil)oxi-2-naftil}metil]-2,4-tiazolidinadiona |
-
1999
- 1999-11-19 PT PT99972628T patent/PT1131310E/pt unknown
- 1999-11-19 CA CA002351727A patent/CA2351727C/en not_active Expired - Fee Related
- 1999-11-19 TR TR2001/01901T patent/TR200101901T2/xx unknown
- 1999-11-19 IL IL14317799A patent/IL143177A0/xx unknown
- 1999-11-19 NZ NZ512429A patent/NZ512429A/en unknown
- 1999-11-19 KR KR1020017006299A patent/KR100652326B1/ko not_active IP Right Cessation
- 1999-11-19 ID IDW00200101331A patent/ID30064A/id unknown
- 1999-11-19 CZ CZ20011763A patent/CZ20011763A3/cs unknown
- 1999-11-19 AT AT99972628T patent/ATE315552T1/de not_active IP Right Cessation
- 1999-11-19 US US09/856,295 patent/US6541493B1/en not_active Expired - Fee Related
- 1999-11-19 TR TR2002/02103T patent/TR200202103T2/xx unknown
- 1999-11-19 HU HU0104139A patent/HUP0104139A3/hu unknown
- 1999-11-19 JP JP2000583883A patent/JP3784001B2/ja not_active Expired - Fee Related
- 1999-11-19 TR TR2002/02109T patent/TR200202109T2/xx unknown
- 1999-11-19 DE DE69929476T patent/DE69929476T2/de not_active Expired - Fee Related
- 1999-11-19 BR BR9916795-6A patent/BR9916795A/pt not_active IP Right Cessation
- 1999-11-19 PL PL99348502A patent/PL348502A1/xx unknown
- 1999-11-19 EP EP99972628A patent/EP1131310B1/en not_active Expired - Lifetime
- 1999-11-19 WO PCT/JP1999/006492 patent/WO2000031055A1/en active IP Right Grant
- 1999-11-19 TR TR2002/02110T patent/TR200202110T2/xx unknown
- 1999-11-19 ES ES99972628T patent/ES2257104T3/es not_active Expired - Lifetime
- 1999-11-19 AU AU11851/00A patent/AU1185100A/en not_active Abandoned
- 1999-11-19 CN CN99813380A patent/CN1326449A/zh active Pending
- 1999-11-20 TW TW088120305A patent/TWI250156B/zh not_active IP Right Cessation
- 1999-11-20 TW TW094136910A patent/TWI272944B/zh not_active IP Right Cessation
-
2001
- 2001-05-18 NO NO20012444A patent/NO20012444L/no not_active Application Discontinuation
- 2001-05-18 ZA ZA200104081A patent/ZA200104081B/en unknown
-
2003
- 2003-01-31 US US10/355,160 patent/US20030158241A1/en not_active Abandoned
-
2006
- 2006-02-21 US US11/357,208 patent/US20060149075A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003093250A3 (en) | Positive allosteric modulators of the nicotinic acetylcholine receptor | |
| RS37603A (en) | Ortho-substituted and meta-substituted bis-aryl compounds, method for the production thereof, theis urse as a medicament and pharmaceutical preparations containing these compounds | |
| ATE269067T1 (de) | Topische formulierungen zur behandlung von nagel pilzerkrankungen | |
| DK0655917T3 (da) | Krystallinske amifostin-præparater og fremgangsmåder til fremstilling og anvendelse af samme | |
| WO2004022523A3 (en) | 1, 3-diamino-2-hydroxypropane prodrug derivatives | |
| NO20045042L (no) | 7-aryl -3,9-diazabicyklo (3.1.1)non-6-en-derivater og deres anvendelse som renin. inhibitorer ved behandling av hypertensjon, kardiovaskulaere og nyresykdommer | |
| NO308248B1 (no) | Forbindelser som er anvendbare som antiproliferative midler og GARFT-inhibitorer, samt farmasøytisk preparat | |
| NO20054974L (no) | 9-azabicyklo(3.3.1)non-6-en derivater med et heteroatom i 3-posisjonen som renin inhibitorer | |
| BR0213139A (pt) | Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica | |
| WO2002016355A3 (en) | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands | |
| HUP0102277A2 (hu) | 3-Helyzetben heterociklusos csoporttal szubsztituált benzoesavszármazékot tartalmazó herbicid készítmény előállítása és alkalmazása | |
| WO2001091738A3 (en) | Naaladase inhibitors for treating amyotrophic lateral sclerosis | |
| NO20015419D0 (no) | Propionsyrederivater som hemmer binding av integriner til deres reseptorer | |
| NO984470L (no) | Pyrrolopyrrolon-derivater som inhibitorer for neutrofil elastase | |
| WO2003006670A3 (en) | 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors | |
| EA200000654A1 (ru) | Гидрат соли малеиновой кислоты 5-[4-[2-(n-метил-n-(2-пиридил)амино) этокси]бензил]-тиазолидин-2,4-диона в качестве фармацевтического препарата | |
| CA2286511A1 (en) | Novel macrolide derivatives | |
| BR9813604A (pt) | Hidrato de sal de ácido maleico 5-[4-[2- (n-metil-n-(2-piridil) amino) etóxi]benzil]tiazolidina-2,4-diona | |
| NO20012444L (no) | Krystaller av 5-[{6-(2-fluorbenzyl)oksy-2-naftyl}metyl]2,4- tiazolidindion, fremgangsmåte for deres fremstilling ogfarmasöytisk preparat omfattende slike | |
| AU2566101A (en) | Compounds and methods for the treatment of pain | |
| EA200101101A1 (ru) | Новый фармацевтический препарат | |
| IE871766L (en) | 4-(aroylamino)piperidinebutanamide derivatives | |
| WO2000056304A3 (en) | Anti-inflammatory uses of manzamines | |
| BR0009898A (pt) | Produto farmacêutico | |
| BR0113713A (pt) | Sal de cloridrato de 5-[4-[2-(metil-n-(2-piridil)amino)etóxi]benzil]tiazolidina -2,4-diona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |